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Abstract There are no special recommendations for basic
vaccinations in patients with chronic neurological deﬁcits
distinct from the nationwide advocated schedule in
Switzerland. Reports describing adverse neurological
events possibly related to vaccinations have attracted
public attention. It is unclear if patients with chronic
neurological deﬁcits are more reluctantly vaccinated
compared to healthy children. We therefore investigated
the acceptance of vaccinations in such patients and
healthy controls in a retrospective case-control study. At
the University Children’s Hospital, Basel, Switzerland we
investigated 100 patients with chronic neurological deﬁ-
cits and 200 age-matched healthy controls regarding the
issue of vaccination rates and ages. The total number of
administered vaccinations against diphtheria, tetanus,
pertussis, polio, Haemophilus inﬂuenzae type b (Hib),
mumps, measles, rubella and hepatitis B were signiﬁ-
cantly lower in patients compared to healthy controls
(P<0.01 for each of the respective vaccines). Patients had
an increased risk to receive the third pertussis, diphtheria,
and tetanus vaccinations (relative risks (RR) for late
vaccination 1.53, 1.53, and 1.54 respectively, P<0.01 for
all comparisons), the second (RR=1.60, P<0.05) and
third Hib vaccinations (RR=1.52, P<0.05), and the
third polio vaccination (RR=1.43, P<0.05) later than
controls. Conclusion: Children with chronic neurological
deﬁcits received fewer vaccinations than healthy controls.
In addition, patients received vaccinations later than
healthy children. Hence, it may be assumed that children
with chronic neurological deﬁcits are at an increased risk
to acquire preventable infections. Therefore, vaccination
should be promoted as part of the consultation during a
routine appointment with the specialist.
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Introduction
Vaccinations prevent infections and their complications
[5]. Many countries have introduced nationwide vacci-
nation schedules. The acceptance of vaccinations is
inﬂuenced by a variety of factors. Missed preventive
visits, and diﬃculties in tracking undervaccinated
patients play a major role in lacking compliance with
recommendations [21]. In addition, children with pre-
existing medical conditions such as premature birth are
vaccinated more reluctantly than full-term born children
[22].
There are no special recommendations regarding the
standard vaccinations for children with chronic diseases
only some speciﬁc explanations and precautions are gi-
ven, for example for pertussis vaccination. Early reports
of adverse neurological events following diﬀerent vac-
cinations have led to a strong reluctance to vaccinate
these patients according to nationwide schedules [2].
However, the reluctance to immunise children with
neurological diseases has not been suﬃciently docu-
mented. Although a controversial issue, available sci-
entiﬁc evidence underlines the importance of vaccination
in children with chronic neurological deﬁcits [7]. With
modern vaccines, serious adverse reactions are extremely
rare and the overall beneﬁt by far outweighs possible
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adverse reactions [13, 16]. Nevertheless, practitioners
and parents often hesitate to vaccinate children with
chronic neurological deﬁcits, possibly due to an
unawareness of guidelines or an unwillingness to put
them into practice [8, 18, 21].
We therefore examined children with chronic neuro-
logical deﬁcits regarding vaccination rate and the latency
of vaccine administration.
Subjects and methods
The University Children’s Hospital of Basel, Switzer-
land, serves children with neurological diseases in
north-western Switzerland (approximately 650,000
inhabitants). Between March 1999 and April 2001, we
accumulated vaccination data of 100 patients in our
neuropaediatric outpatient clinic. After approval by the
local Ethics Committee, patients with various chronic
neurological diseases were collected to obtain infor-
mation on the acceptance of vaccination in this group
of patients and to avoid reservation concerning par-
ticular neurological diseases. We included patients with
chronic neurological deﬁcits at the age of 1 to 16 years.
As controls we collected 200 primarily healthy age-
matched children who presented with an acute illness in
our general outpatient clinic. Data of patients and
controls were gathered by convenience sampling. The
patients and controls were representative of all children
in this geographic area. All children were raised in
north-western Switzerland. Excluded were children with
other chronic diseases or premature birth.
After oral informed consent, parents were asked to
present a copy of their children’s vaccination certiﬁcate.
Minimisation of selection bias in the patient group was
achieved since 100% of parents who were asked to
participate in fact consented to submit their children’s
vaccination certiﬁcates. The sample of healthy controls
was potentially more prone to residual selection bias
since primarily those patients were enrolled whose par-
ents had their children’s vaccination certiﬁcates with
them during the outpatient clinics visit.
We restricted our study to those vaccinations sug-
gested by the Swiss committee for immunisation rec-
ommendations, namely diphtheria, tetanus, pertussis
(DTP), polio, Haemophilus inﬂuenzae type b (Hib),
mumps, measles, rubella (MMR), and hepatitis B (hep
B). While the study was performed, four vaccinations
against polio, diphtheria and tetanus, and Hib and three
against pertussis were recommended in Switzerland
during the ﬁrst 2 years of life. Recommended vaccina-
tion ages were 2, 4, 6, and 15–24 months for polio, DTP
and Hib. One vaccination against MMR was recom-
mended between 12 and 24 months of age. Children
older than 11 years had to be vaccinated against hep B
three times [9] (n=66 in this study). Analyses of vacci-
nations against Hib were restricted to patients and
respective controls born in 1987 or later (n=270) since
the vaccine became available no earlier than 1991.
Children born in 1987 or later were recommended to
catch up on Hib vaccinations.
Statistical evaluation
Primary evaluation parameters were vaccination rate
and age of the entire patient population compared to
age-matched healthy controls. Triplets were built con-
sisting of one patient and two age-matched controls.
Simple rates were calculated for all vaccinations. Vac-
cination rates were evaluated within the triplets with the
patient value being compared to the mean of the two
respective control values. The Wilcoxon signed rank test
was used for symmetric data (sign test for asymmetric
data) to determine whether average within triplet dif-
ferences in vaccination parameters between patients and
controls were statistically diﬀerent from 0. All tests were
performed two-sided at a signiﬁcance level of 5%.
To determine vaccination age we counted the days
from the date of birth to the date of each performed
vaccination. Survival-analytical methods were used to
compare vaccination ages. Vaccinations were considered
as events. In the case of missing vaccinations, time to
vaccination was censored by the subject’s age at the day
of our examination. The inﬂuence of being a patient on
time to vaccination was then assessed using Cox
regression models with an individual baseline hazard
function estimate for each triplet.
A subset of patients was chosen according to age at
the time of diagnosis (congenital plus diagnosis within
the ﬁrst 6 months of life, n=66) to investigate vaccina-
tion patterns in more detail.
We also examined if patients and controls were vac-
cinated within a timeframe compatible with the pub-
lished recommendations. Since only the ﬁrst three
vaccinations against DTP, Hib, polio, and the ﬁrst
vaccination against MMR are recommended to be
administered at a particular age, we restricted our
analysis to these vaccinations. We subtracted the rec-
ommended vaccination age from the child’s age at vac-
cination and tested whether the population mean of the
resulting number of days was signiﬁcantly diﬀerent from
zero using t-tests for unpaired samples. This was done
separately for patients and healthy controls and in both
groups for only those subjects who received the respec-
tive vaccinations. Analyses account for all changes of
recommended vaccination ages in Switzerland between
1986 and 2000.
Results
Patient characteristics
Patients were between 1 and 16 years old (Table 1). A
total of 55 patients had congenital abnormalities and 45
acquired a chronic neurological deﬁcit during the ﬁrst 4
years of life. In these patients, median age at diagnosis
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was 1.4 years (range 20 days–4.0 years). The most fre-
quent deﬁcits were epilepsy (39%), cerebral palsy (11%),
degenerative and metabolic aﬀections of the central
nervous system (10%), and recurrent febrile seizures
(10%).
Vaccination rate
Patients with congenital neurological deﬁcits or a diag-
nosis within the ﬁrst 6 months of life (n=66) had sub-
stantially lower vaccination rates than age-matched
healthy controls (n=132). Over 88% of patients and
healthy controls received the ﬁrst three doses of polio,
diphtheria and tetanus vaccine. Pertussis, Hib, MMR,
and hep B vaccines were less frequently administered.
Except for the ﬁrst dose of polio and T, patients had
lower vaccination rates than healthy controls. This was
statistically signiﬁcant for the third doses of diphtheria
and tetanus. All four doses of pertussis vaccine were
administered to patients less often than to controls with
a statistical signiﬁcance for the ﬁrst three doses (Ta-
ble 2).
Vaccination age
Children with chronic neurological deﬁcits were at an
increased risk for being vaccinated against DTP, polio,
and Hib later than age-matched healthy controls
(Fig. 1). Patients had an increased risk of 36% and
31% of receiving the ﬁrst and second dose of pertussis
vaccine later than controls. A 54% increased risk of
receiving the third vaccination late was statistically
signiﬁcant (P<0.01). A very similar picture evolved
for the comparison between patients and controls for
vaccinations against diphtheria, tetanus and polio. In
addition, patients were at a 60% increased risk
(P=0.01) to receive the second, and at a 52% in-
creased risk (P<0.05) to receive the third dose of Hib
vaccine later than controls. For MMR and hep B
vaccinations, patients had no statistically signiﬁcant
increased risk to receive the dose delayed compared to
healthy controls (Fig. 1).
Compliance with vaccination recommendations
Patients and healthy controls received the analysed
vaccinations later than recommended by oﬃcial Swiss
guidelines. The ﬁrst vaccinations against DTP, and
polio were administered with approximately 3 months
delay. The ﬁrst Hib and the MMR vaccinations were
also administered with latency compared to the rec-
ommended vaccination ages. In patients, the ﬁrst
vaccination against Hib was given 115±59 days and
the vaccination against MMR 56±24 days later than
recommended (P<0.05). In healthy children, the re-
spective vaccinations were administered 38±5 and
52±10 days later than recommended (P<0.01). The
second and third vaccinations against DTP, polio, and
Hib were given with a delay of 89 to 188 days in
patients and 40 to 155 days in healthy controls. In
most instances these diﬀerences from the re-
commended vaccination dates were statistically sig-
niﬁcant. As a generally applicable example of
vaccination coverage we display an inverse Kaplan-
Meier plot [15] for the third dose of pertussis vaccine
(Fig. 2).
Table 2 Vaccination rates (%) of patients with congenital neuro-
logical diseases or diagnosis within the ﬁrst 6 months of life com-
pared to age-matched healthy controls
Vaccination Dose 1 Dose 2 Dose 3 Dose 4
Diphtheria
Patients (n =66) 97 96 89* 70
Controls (n =132) 99 99 97 78
Tetanus
Patients (n =66) 99 97 91* 68
Controls (n =132) 99 99 98 79
Pertussis
Patients (n =66) 86* 83* 71** 36
Controls (n =132) 95 92 89 49
Polio
Patients (n =66) 99 97 88 70
Controls (n =132) 99 99 96 78
Hib
Patients (n =58) 92 80 69 23
Controls (n =116) 94 88 82 35
MMR
Patients (n =66) 70 8
Controls (n =132) 79 14
Hep B
Patients (n =12) 8 8 0
Controls (n =24) 16 16 12
* P <0.05 compared to healthy controls
** P <0.01 compared to healthy controls
Table 1 Demographic data of patients with chronic neurological
diseases and age-matched healthy controls
Patients (n =100) Controls (n =200)
Gender
(male/ female)
59% / 41% 55% / 45%
Ethnicity Switzerland (79%) Switzerland (83%)
Turkey (15%) Turkey (7%)
Sri Lanka (2%) Sri Lanka (3.5%)
Yugoslavia (2%) Yugoslavia (3%)
Italy (1%) Italy (2.5%)
Germany (1%) Germany (0.5%)
Togo (0.5%)
Main diagnoses Epilepsy (39%) Not applicable
Cerebral palsy (24%)
Severe developmental
delay (17%)
Recurrent complicated
febrile seizures (10%)
Neurodegenerative,
metabolic diseases (6%)
Myopathies (4%)
Mean age (years ±
standard error)
6.7±0.4 6.7±0.3
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Discussion
Vaccines against hep B, Hib, MMR, and especially
pertussis have been suspected to cause severe illness and
in particular neurological diseases [2, 6, 11, 17, 19].
Large-scale epidemiological studies have failed to con-
ﬁrm these allegations [7, 20].
Our data express a clear warning sign: patients with
underlying chronic neurological deﬁcits receive fewer
DTP, polio, Hib, MMR, and hep B vaccinations com-
pared to healthy controls (Table 2). This ﬁnding may
partly be explained by a study investigating paediatric
and family residents’ intention to vaccinate children with
neurological diseases. Physicians reported a lower like-
lihood to vaccinate children with a neurological condi-
Fig. 1 Vaccination age/risk
ratio for late vaccination in
patients with chronic
neurological disease (n=100)
compared to age-matched
healthy controls (n=200). All
risk ratios are presented as
point estimates ( solid diamonds)
with 95% conﬁdence intervals
in comparison to controls with
the predeﬁned control value
=1. ** P <0.01, * P <0.05,
compared to healthy controls
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tion [4, 14]. The authors support an intensiﬁed education
of residents regarding vaccination issues.
Febrile seizures have been reported after receipt of
DTP (whole cell) or MMR vaccine but there was no
association with long-term side-eﬀects [1]. The modern
acellular compared to whole cell pertussis vaccines in-
duce less side-eﬀects [10, 12]. Nevertheless, children in
our study received fewer doses of pertussis than diph-
theria, tetanus, and polio vaccine. A low vaccination
rate against pertussis may be due to an underestimation
of potentially deleterious sequelae following Bordetella
pertussis infection [3]. We speculate that a historic
scepticism against pertussis vaccination originating from
the era of whole cell pertussis vaccines still inﬂuences the
acceptance of modern vaccines [17]. Patients with
chronic neurological deﬁcits and especially children with
congenital neurological deﬁcits or a diagnosis within the
ﬁrst 6 months of life received fewer vaccinations than
controls (Table 2). This reﬂects an additional risk to
acquire B. pertussis infections. However, it has to be
kept in mind that the older children in our study pop-
ulation were initially vaccinated with whole cell pertussis
vaccine in the early 1990’s.
Our results on vaccination ages further corroborate
the above assumptions. Patients were at an approxi-
mately 30% to 50% increased risk to receive pertussis
vaccinations later than controls (Fig. 1). For presum-
ably similar reasons, Hib vaccinations were administered
less often than other vaccinations in the entire examined
population. It has to be considered that since 1995,
monovalent Hib vaccines (given twice in the ﬁrst and
once in the second year of life) have been gradually
substituted by DTP-Hib combination vaccines (four
dose schedule, three doses in the 1st year of life).
Additionally, children born before 1991 were recom-
mended to catch up on all Hib doses. Furthermore, a
particularly high risk for late vaccination was apparent
for the second and third Hib vaccination (Fig. 1).
The ﬁnding that vaccination rates against MMR were
similarly low among patients and healthy controls is in
line with earlier results for the whole of Switzerland [3].
Low vaccination rates against hep B in patients and
controls, recommended at the age of 11 years onwards,
may be due to the recent introduction in 1997 of this
vaccine into nationwide recommendations. Neverthe-
less, rates for the respective doses between 16% and 0%
(Table 2) are alarming, particularly for chronically dis-
abled children who are more likely to be in contact with
hep B. Vaccination campaigns have obviously not had
the desired eﬀect as yet since there has been no mea-
surable increase in vaccination rates compared to 1998
[3]. Therefore, we strongly advocate further attempts to
positively change hep B vaccination acceptance.
Another aspect with public health impact is high-
lighted by our data on the conformity of vaccination
dates with the recommended vaccination dates. All
examined vaccinations were given later than promoted
by guidelines. We were alerted by the fact that many
vaccinations were administered as late as 4 to 6 months
after the recommended vaccination age in both groups.
This was particularly obvious for pertussis (Fig. 2).
During this considerable period, children have no ade-
quate protection against the respective diseases. Since all
children were aﬀected by this reluctance to vaccinate
according to guidelines, we suggest an energetic eﬀort by
public health agencies aimed at physicians and parents
to emphasise the importance of timely vaccinations.
In conclusion, our data show that children with
chronic neurological deﬁcits in north-western Switzer-
land received less vaccinations and were vaccinated later
than age-matched healthy controls. This may entail an
increased risk for community-acquired infections. To-
day, vaccinations can be considered safe but the indi-
cation to vaccinate should be determined on an
individual basis. The eﬀectiveness of vaccination is
dependent on the personal engagement of the primary
Fig. 2 Coverage of pertussis
vaccination (dose 3) in children
with chronic neurological
deﬁcits (n=100) compared to
age-matched healthy controls
(n=200) in north-western
Switzerland. The right side of
the shaded area marks the
nationally recommended age-
period for vaccination 3 (at the
age of 5 months)
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care provider [23] whose role may be taken over by a
specialist in children with chronic diseases. Since spe-
cialists sometimes tend to neglect general patient care
aspects such as vaccinations during an appointment, it
has to be stressed that they are obliged to recommend or
even provide vaccinations.
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